tbuckley/cabot-search huggingface dataset:
Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response
Authors: Heather Landau, Hani Hassoun, Adam Cohen, Elizabeth Hoover, Tarun Kewalramani, Adam Boruchov, Virginia Klimek, Lillian Reich, Elyn Riedel, Neeta Pandit-Taskar, Stephen D. Nimer, Raymond L. Comenzo
Journal: Blood (2008)
Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy
Authors: Valeria Visconte, Ali Tabarroki, Edy Hasrouni, Yang Liu, Betty K. Hamilton, Craig A. Portell, Edward A. Copelan, Anjali Advani, Mikkael A. Sekeres, Ramon V Tiu
Journal: Blood (2012)
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis
Authors: Paola Storti, Irma Airoldi, Marina Bolzoni, Mirca Lazzaretti, Daniela Guasco, Luca Agnelli, Eugenia Martella, Cristina Mancini, Antonino Neri, Gaetano Donofrio, Nicola Giuliani
Journal: Blood (2011)
P3.02c-100 Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Authors: Miguel Sotelo, Luis Chara, Alejandro Riquelme, Piedad Toro, Cynthia López, Susana Hernando, Edinson Caviedes, Cristina Aguayo, Coralia Bueno, Xabier Mielgo Rubio
Journal: Journal of Thoracic Oncology (2017)
S135 Circulating metabolites in chronic thromboembolic pulmonary hypertension and chronic thromboembolic pulmonary vascular occlusion
Authors: KI Zalewska, EM Swietlik, J Sanchez Hernandez, JE Cannon, D Taboada, M Newnham, C Hadinnapola, NW Morrell, MR Toshner, J Pepke Zaba
Journal: Thorax (2016)

<h3>Introduction</h3> Recent studies have demonstrated that metabolomic profiling can identify metabolites and pathways which may have importance in the pathobiology of pulmonary arterial hypertension. However, the plasma metabolome in chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic vascular occlusions without pulmonary hypertension (CTED) has not been well characterised. <h3>Objective</h3> To profile circulating metabolites in CTEPH and CTED and assess metabolite gradients across the pulmonary circulation. <h3>Methods</h3> In the patient group, multisite blood sampling was performed at the time of right heart catheterisation. Blood samples were collected from the superior vena cava, pulmonary artery and radial artery. Venous blood samples from patients were compared to healthy controls to identify the metabolites present and to assess the difference between health and disease. Additionally, in the disease group, transpulmonary gradients were assessed by analysis of fold change in metabolite concentration between paired samples from the pulmonary artery and radial artery. Untargeted, semi-quantitative metabolic profiling of plasma was performed using the Metabolon DiscoveryHD4™ platform (Metabolon, NC, USA), utilising 2 ultra-high performance liquid chromatography methods, coupled with tandem mass spectrometry. Kruskal-Wallis analysis was used to compare metabolites between disease and control, with false discovery rate correction for multiple testing. <h3>Results</h3> The disease group included patients with a spectrum of chronic pulmonary vascular occlusions (Table 1). A total of 1375 metabolites were detected in 70 venous plasma samples analysed from 43 patients and 27 healthy controls. Amongst endogenous metabolites, 266 showed a significant difference between disease and control. In the disease group there were increases in acylcarnitine metabolites, long chain fatty acids, polyamines, glycogen metabolites and primary bile acid metabolites compared to healthy controls. There was a reduction in lysolipids, plasmalogens, aminosugars, branched chain amino acid metabolites, glutathione metabolites and a number of steroids (Table 1). Analysis of transpulmonary gradients revealed primarily a reduction in metabolite concentration across the pulmonary circulation. This included depletion of energy substrates, lysolipids, lysoplasmalogens and acylcholines. <h3>Conclusions</h3> This pilot study of circulating metabolites in patients with CTEPH, CTED and healthy controls reveals differences between health and disease in several biological pathways. Measurement of the transpulmonary gradient of metabolites indicated predominant clearance of circulating metabolites associated with energy metabolism and cell turnover. These findings require confirmation in a larger population.
Effects of bisphosphonates and insulin-like growth factor-1 (IGF-1) on prostate cancer cells in vitro
Authors: J. C. Dumon, N. Kheddoumi, L. Lagneaux, F. Journé, J. Body
Journal: Journal of Clinical Oncology (2004)

4758 Background: The bisphosphonate (BP) zoledronic acid (Zol) reduces skeletal morbidity from metastatic bone disease in patients with prostate cancer, presumably through inhibition of osteolysis. Osteolysis undermines skeletal integrity and releases IGF-1, thus stimulating prostate cancer growth. In addition, BPs have been shown to inhibit cancer cell growth. Therefore, we investigated the effects of BPs on prostate cancer cell growth in vitro. Methods: The effects of clodronate (Clod), pamidronate (Pam), ibandronate (Iban), and Zol on human PC-3 cell growth and survival were investigated after 1–6 days in culture. Cells were grown in media containing 1 to 100 microM BPs in the absence or presence (for Clod and Zol only) of 100 ng/mL IGF-1. Cell survival and growth were assessed by MTT assay, DNA content, and crystal violet staining. Proportion of cells in G0/G1 phase was determined by fluorescent staining, and apoptotic cells were identified by annexin staining. Results: Cell survival was not affected by Clod, but decreased in a time- and dose-dependent manner with Pam, Iban, and Zol. The largest effect was observed after 6 days with 100 microM Zol. Clod and Pam had no significant effect on cell cycle distribution. In contrast, 100 microM Zol or Iban produced cell accumulation in G0/G1 after 1, 2, and 4 days. The percentage of apoptotic cells was increased 2-fold by both Pam and Zol, and 1.3-fold by Iban. Clod had no effect. In the presence of IGF-1, cell growth increased by 28% (standard error of the mean [SEM] = 5%) at day 2 and by 23% (SEM = 7%) at day 6 (P < .001). These mitogenic effects were blocked by 1 microM Zol. Cell proliferation in the presence of IGF-1 was blocked by 10 microM Zol, and 100 microM Zol resulted in 85% cell death at day 6. Mitogenesis by IGF-1 was blocked by 10 microM Clod, but cell growth was not inhibited even at 100 microM Clod. Conclusions: Therefore, BPs, especially Zol, have direct effects on prostate cancer cells, inhibiting growth through cytostatic, apoptotic, and antimitogenic activities. These activities could contribute to the beneficial effects of Zol in the treatment of prostate cancer-induced bone disease. No significant financial relationships to disclose.
P2.02-051 Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non-Small Cell Lung Cancer
Authors: Ivona Markelić, Lela Bitar, Fran Seiwerth, Branka Čučević, Suzana Kukulj, Sanja Plestina, Fedza Dzubur, Miroslav Samarzija, Marko Jakopovic
Journal: Journal of Thoracic Oncology (2017)
Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
Authors: Luciano Castiello, Marianna Sabatino, Jiaqiang Ren, Masaki Terabe, Hanh Khuu, Lauren V. Wood, Jay A. Berzofsky, David F. Stroncek
Journal: Clinical Cancer Research (2017)

Purpose: Despite the vast number of clinical trials conducted so far, dendritic cell (DC)-based cancer vaccines have mostly shown unsatisfactory results. Factors and manufacturing procedures essential for these therapeutics to induce effective antitumor immune responses have yet to be fully characterized. We here aimed to identify DC markers correlating with clinical and immunologic response in a prostate carcinoma vaccination regimen.Experimental Design: We performed an extensive characterization of DCs used to vaccinate 18 patients with prostate carcinoma enrolled in a pilot trial of T-cell receptor gamma alternate reading frame protein (TARP) peptide vaccination (NCT00908258). Peptide-pulsed DC preparations (114) manufactured were analyzed by gene expression profiling, cell surface marker expression and cytokine release secretion, and correlated with clinical and immunologic responses.Results: DCs showing lower expression of tolerogenic gene signature induced strong antigen-specific immune response and slowing in PSA velocity, a surrogate for clinical response. These DCs were also characterized by lower surface expression of CD14, secretion of IL10 and MCP-1, and greater secretion of MDC. When combined, these four factors were able to remarkably discriminate DCs that were sufficiently potent to induce strong immunologic response.Conclusions: DC factors essential for the activation of immune responses associated with TARP vaccination in prostate cancer patients were identified. This study highlights the importance of in-depth characterization of DC vaccines and other cellular therapies, to understand the critical factors that hinder potency and potential efficacy in patients. Clin Cancer Res; 23(13); 3352-64. ©2017 AACR.
The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival.
Authors: Christopher P. Venner, Heather Sutherland, John Shepherd, Yasser Abou Mourad, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Janet Nitta, Maryse Power, Cynthia Toze, Clayton Smith, Kevin Song
Journal: Blood (2010)
Prevalence and trajectory of disease- and treatment-related symptom burden in patients with multiple myeloma undergoing induction therapy.
Authors: R. Z. Orlowski, X. S. Wang, T. R. Mendoza, L. A. Williams, V. E. Johnson, J. Joy, V. Ilagan, G. M. Mobley, P. Liu, K. R. Gilmore, C. S. Cleeland
Journal: Journal of Clinical Oncology (2011)

e19627 Background: Patients with multiple myeloma (MM) undergoing induction therapy experience both disease- and therapy-related symptoms. This study selectively focused on the trajectory of pain, fatigue, numbness and bone aches from patient-reported outcome. Methods: MM patients (N=62) repeatedly rated symptoms via the M. D. Anderson Symptom Inventory (MDASI) (twice a week for 12 weeks, then weekly for 6 weeks). Ordinal regression analysis was used to describe symptom trajectories across time. Group-based trajectory modeling was used 1) to estimate the proportion of MM patients belonging to high, medium or low group by symptom severity; and 2) to examine the patterns of each group derived for each symptom. Results: During induction period, fatigue was persistently the most severe symptom, while therapy-induced neuropathy (MDASI numbness item) increased significantly from baseline (P=.0008). Group-based trajectory modeling resulted in 3 groups as the best model fit for 4 symptoms. The proportions of patients categorized as having high, medium or low symptom severity, respectively, were: for pain, 27%, 41% and 32%; for bone ache, 22%, 43% and 35%; for numbness, 22%, 48% and 30%; for fatigue, 28%, 58% and 14%. For pain, we observed a significant linear increased trend in the medium group (P<.001). For fatigue, bone ache and numbness, the medium and low groups exhibited only a slight change in slope, while the high symptom group showed a significant initial increase followed by a decrease trend (all quadratic trends, P<.001). Other than baseline performance status (P<.01), no clinical or patient factor was related to group membership. Conclusions: The majority of patients reported moderate or greater fatigue, pain and bone aches throughout the induction treatment, with little evidence of reduction, while numbness/tingling dramatically increased over time. We also observed that some MM patients persistently reported low symptom burden compared to others, despite similar disease burden and therapy. These results warrant further translational studies to identify biomarker(s) related to high symptom burden, so as to guide personalized patient care during standard induction therapy.
The Wiskott Aldrich Syndrome Protein (WASP) Is Involved in Dexamethasone-Signalling Pathways Leading to Apoptosis of Multiple Myeloma Cells and in Cell Adhesion Mediated Drug Resistance Against Dexamethasone
Authors: Hazera Khatun, Amna Anwar, Majid A. Kazmi, Stephen Schey, Yolanda Calle
Journal: Blood (2011)
Improvements in Fatigue Are Associated with Early Treatment with Every-3-Week (Q3W) Darbepoetin alfa (DA) Treatment in Anemic Patients (pts) Receiving Chemotherapy (Ctx).
Authors: V. Charu, B. Saidman, A. Ben-Jacob, G. R. Justice, A. S. Maniam, T. Rearden, D. Tomita, G. Rossi
Journal: Blood (2004)
Targeting the Protein Phosphatase, Shp2, Reduces FLT3-ITD-Induced Hyperproliferation of Murine Hematopoietic Progenitors.
Authors: Sarah C Nabinger, Yantao He, Fuqin Yin, Xian Zhang, Linda Senbanjo, Seiji Fukuda, Menggang Yu, Gen-Sheng Feng, Zhong-Yin Zhang, Reuben Kapur, Rebecca J. Chan
Journal: Blood (2009)
P1.05-078 The Relationship between IASLC/ATS/ERS Grading System of Adenocarcinoma of the Lung and Quantitive PET Parameters
Authors: Ülkü Yılmaz, Özlem Özmen, Funda Demirağ, Tuba Inal Cengiz, Pınar Akın Kabalak, Derya Kızılgöz, Ibrahim Onur Alıcı, Göktürk Fındık
Journal: Journal of Thoracic Oncology (2017)
P2.03b-088 PET-CT with 68Ga-RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC
Authors: Oscar Arrieta, Francisco García-Pérez, David Michel-Tello, Laura-Alejandra Ramírez-Tirado, Denisse Lee-Cervantes, Quetzali Pitalua-Cortes, Omar Macedo-Pérez, Graciela Cruz-Rico
Journal: Journal of Thoracic Oncology (2017)
Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.
Authors: Sylvain Thépot, Raphael Itzykson, Valerie Seegers, Christian Recher, Bruno Quesnel, Jacques Delaunay, Thomas Cluzeau, Anne Marfaing Koka, Aspasia Stamatoullas, MP Chaury, Caroline Dartigeas, Stéphane Cheze, Celia Salanoubat, Pierre Morel, Isabelle Plantier, Anne-Laure Taksin, Jean Pierre Marolleau, Cecile Pautas, Eric Wattel, Francoise Isnard, Laurence Sanhes, Stephanie Harel, Stephane de Botton, Yasmine Chait, Madalina Uzunov, Agnes Guerci, Mehdi Dahoun, Norbert Vey, Herve Dombret, Francois Dreyfus, Lionel Ades, Pierre Fenaux, Claude Gardin
Journal: Blood (2009)
A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population
Authors: Timothy J George, Joseph E Woolery, Gene A. Wetzstein, Viet Q. Ho, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji
Journal: Blood (2010)
P2.01-026 A Mass Spectrometry Based Stem Cell-Oriented Phylogeny of Intra-Tumoral NSCLC Subclones
Authors: Robert Downey, Erin Seeley, Andre Moreira, Hua-Jun Wu, Charlotte Lee, Prasad Adusumilli, Greg Kilby, Franziska Michor
Journal: Journal of Thoracic Oncology (2017)
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC
Authors: Rafal Dziadziuszko, Dong-Wan Kim, Alessandra Bearz, Scott Laurie, Mark Mckeage, Keunchil Park, Sang-We Kim, Vanessa Q. Passos, Karen Osborne, Yvonne Y. Lau, Jessie Gu, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2017)
Little White Lies
Authors: Daniel F. Chen
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial
Authors: Gregory L Calligaro, Lynn S Zijenah, Jonathan G Peter, Grant Theron, Virginia Buser, Ruth McNerney, Wilbert Bara, Tsitsi Bandason, Ureshnie Govender, Michele Tomasicchio, Liezel Smith, Bongani M Mayosi, Keertan Dheda
Journal: The Lancet Infectious Diseases (2017)
Antibodies Causing Thrombocytopenia in Patients Given RGD-Mimetic Platelet Inhibitors Recognize Drug-Induced (and drug-specific) Conformational Epitopes Adjacent to the RGD Recognition Site of Gpiib/Iiia.
Authors: Daniel W. Bougie, Mark Rasmussen, Jessica Ruben, Richard H. Aster
Journal: Blood (2009)
Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.
Authors: G. Anandappa, E. Sala, H. K. Cheow, N. J. Bird, A. Shaw, A. N. Priest, A. Gill, T. Fryer, Y. T. Hong, R. Smith, A. Backen, B. Whitcher, A. Jonson, D. Richards, L. Cookson, W. M. F. Lee, C. Dive, K. M. Fife, D. I. Jodrell, T. Eisen
Journal: Journal of Clinical Oncology (2011)

TPS155 Background: In recent years rationally designed targeted molecules have improved progression free survival in selected tumour types. These agents are primarily cytostatic and it is increasingly obvious that ‘conventional’ pharmacodynamic (PD) end points are no longer adequate in evaluating their activity. The incorporation of novel PD biomarkers in proof of mechanism early phase studies to confirm desired target effect is increasingly frequent, as these may serve as early indicators of drug activity and facilitate early go/no-go decisions in drug development. In this study, imaging biomarkers of tissue perfusion and hypoxia are being used to assess the PD effects of bevacizumab, a humanised anti-VEGF monoclonal antibody. Plasma biomarkers are being used to compare the PD effects of bevacizumab, with those of the multi-targeted tyrosine kinase inhibitor, pazopanib in patients with renal cancer. Methods: This is a single-centre, two-part, exploratory study. Eligibility criteria include patients with histologically proven unresectable renal cell cancer with a clear cell component, with documented evidence of disease progression on ≥ 1st first line, ≥ 18 years of age, ECOG performance status 0-1, with evidence of unidimensionally measurable disease ≥ 10mm on CT or MRI; with adequate bone marrow, liver and renal function. A total of 12 patients will be enrolled. In part I, patients receive 3 infusions of bevacizumab (10 mg/kg), administered at 2-week intervals. The PD response to bevacizumab is evaluated over 6 weeks using imaging techniques including dynamic contrast-enhanced (DCE) and diffusion weighted (DW) MRI scans, computed tomography and positron emission tomography (PET-CT) with [15O]Water, [18F]F-fluoromisonidazole, and [18F]-fluoro-2-deoxy-D-glucose tracers; intratumoral VEGF signaling by immunohistochemistry; and circulating biomarkers. Changes in tumor perfusion as assessed by estimation of Ktrans by DCE-MRI is a primary endpoint. In part II, patients receive pazopanib, in escalating doses, and 800mg during a maintenance phase, with PD response evaluated using circulating biomarkers. The study is on-going and we have recruited 6 patients to date. The clinical trial registry number is NCT00992121.
Identification and Cloning of Novel Mutations In a Compound Heterozygous Factor V Deficient Patient
Authors: Kimberley Talbot, Jina Song, Lily Eghdami, Jessica Tamura-Wells, Jeff Hewitt, Linda Vickars, Cedric John Carter, Ross T.A. MacGillivray, Ed L.G. Pryzdial
Journal: Blood (2010)
Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant
Authors: Nebu Koshy, Sebastian A. Mayer, Adrienne Phillips, Rosanna Ferrante, Ronit Slotky, Usama Gergis, Hanna Rennert, Melissa M. Cushing, Tsiporah B. Shore, Koen van Besien
Journal: Blood (2015)
P2.01-035 Protein and Molecular Alterations in EMT Pathways of Lung Cancer: A Comparative Analysis between NSCLCs
Authors: Juliana Machado, Daniel Ascheri, Patrícia Leao, Priscila Milsoni, Rogerio Oliveira, Edwin Parra, Vanessa Sá, Cecília Farhat, Alexandre Ab'saber, Maria Nagai, Teresa Takagaki, Alexandre Fabro, Vera Capelozzi
Journal: Journal of Thoracic Oncology (2017)
P2.02-031 Survival Data of Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine for Completely Resected NSCLC: A Retrospective Study
Authors: Hirotsugu Kenmotsu, Yasuhisa Ohde, Akira Ono, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Tateaki Naito, Haruyasu Murakami, Hideaki Kojima, Shoji Takahashi, Mitsuhiro Isaka, Masahiro Endo, Toshiaki Takahashi
Journal: Journal of Thoracic Oncology (2017)
SC14.04 The CD47 Macrophage Checkpoint as a New Immunotherapy Target
Authors: Branimir I. Sikic, Sukhmani K. Padda, Sumit A. Shah, A. Dimitros Colevas, Sujata Narayanan, George A. Fisher, Dana Supan, Heather A. Wakelee, Rhonda Aoki, Mark D. Pegram, Victor M. Villalobos, Jie Liu, Chris Takimoto, Mark P. Chao, Jens P. Volkmer, Ravindra Majeti, Irving L. Weissman
Journal: Journal of Thoracic Oncology (2017)